Mount Laurel, NJ (January 2, 2020) — PMC Group N.A., Inc. (“PMC”) and Lanxess Organometallics GmbH (“Lanxess”) have announced that PMC has acquired Lanxess’ organotin specialties product line (the “Business”). The transaction, previously reported on November 13, 2019, has closed effective December 30, 2019. The Business included Lanxess’ global organotin catalyst, organotin specialties and intermediates product

MOUNT LAUREL, NJ (November 13, 2019) — PMC Group N.A., Inc. (“PMC”) and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing

MOUNT LAUREL, NJ (January 16, 2019) — PMC Ouvrie SAS, France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of a hydrocolloid product line from the Belgium based Solvay, SA. These products will be sold globally to the home and personal care

VERT-LE-PETIT, FRANCE (March 12, 2018) — Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services from the polypeptide design up to delivery of small quantity of polymer and PMC Isochem will use GMP production facility for clinical batch and commercial supply. In addition, PMC Isochem develops and